103 related articles for article (PubMed ID: 19135168)
1. Monitoring the amyloid beta-peptide in vivo--caveat emptor.
Thompson PW; Lockhart A
Drug Discov Today; 2009 Mar; 14(5-6):241-51. PubMed ID: 19135168
[TBL] [Abstract][Full Text] [Related]
2. Imaging and in vivo quantitation of beta-amyloid: an exemplary biomarker for Alzheimer's disease?
Nichols L; Pike VW; Cai L; Innis RB
Biol Psychiatry; 2006 May; 59(10):940-7. PubMed ID: 16487944
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's biomarker initiative hits its stride.
Miller G
Science; 2009 Oct; 326(5951):386-9. PubMed ID: 19833956
[No Abstract] [Full Text] [Related]
4. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
5. [From neuropathology to biomarker development in Alzheimer research].
Arai H
Rinsho Shinkeigaku; 2006 Nov; 46(11):931-4. PubMed ID: 17432224
[TBL] [Abstract][Full Text] [Related]
6. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
7. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
[TBL] [Abstract][Full Text] [Related]
8. CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease.
Ceravolo R; Borghetti D; Kiferle L; Tognoni G; Giorgetti A; Neglia D; Sassi N; Frosini D; Rossi C; Petrozzi L; Siciliano G; Murri L
Brain Res Bull; 2008 May; 76(1-2):80-4. PubMed ID: 18395614
[TBL] [Abstract][Full Text] [Related]
9. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease.
Phivilay A; Julien C; Tremblay C; Berthiaume L; Julien P; Giguère Y; Calon F
Neuroscience; 2009 Mar; 159(1):296-307. PubMed ID: 19135506
[TBL] [Abstract][Full Text] [Related]
10. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
[TBL] [Abstract][Full Text] [Related]
11. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
[TBL] [Abstract][Full Text] [Related]
12. Disease-modifying therapies for Alzheimer disease: challenges to early intervention.
Cummings JL; Doody R; Clark C
Neurology; 2007 Oct; 69(16):1622-34. PubMed ID: 17938373
[TBL] [Abstract][Full Text] [Related]
13. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
[TBL] [Abstract][Full Text] [Related]
14. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease.
Boissonneault V; Filali M; Lessard M; Relton J; Wong G; Rivest S
Brain; 2009 Apr; 132(Pt 4):1078-92. PubMed ID: 19151372
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers in Alzheimer's disease drug development.
Cummings JL
Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
[TBL] [Abstract][Full Text] [Related]
16. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
[TBL] [Abstract][Full Text] [Related]
17. Concept of functional imaging of memory decline in Alzheimer's disease.
Drzezga A
Methods; 2008 Apr; 44(4):304-14. PubMed ID: 18374274
[TBL] [Abstract][Full Text] [Related]
18. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
19. Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid.
Englund H; Degerman Gunnarsson M; Brundin RM; Hedlund M; Kilander L; Lannfelt L; Pettersson FE
Neurodegener Dis; 2009; 6(4):139-47. PubMed ID: 19521063
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of Z-ligustilide against amyloid beta-induced neurotoxicity is associated with decreased pro-inflammatory markers in rat brains.
Kuang X; Du JR; Chen YS; Wang J; Wang YN
Pharmacol Biochem Behav; 2009 Jun; 92(4):635-41. PubMed ID: 19324070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
